• 5 min read
• Published on 4 August 2025
Listen to article
6:38Hey! We are Nemo.
Nemo, short for Never Miss Out, is a mobile investment platform that delivers curated, data-driven investment ideas to your fingertips. It offers commission-free trading across stocks, ETFs, crypto, and CFDs, along with AI-powered tools, real-time market alerts, and themed stock collections called Nemes.
Download the App
Scan the QR code to download the Nemo app and start investing on Nemo today
Published on 12 September 2026
Read article
Published on 12 September 2026
Read article
Published on 12 September 2026
Read article
Published on 11 September 2026
Read article
Published on 11 September 2026
Read article
For decades, it seems the pharmaceutical giants have been living it up at the most exclusive party in town. The champagne, or rather, the profits, have flowed freely, funded by a pricing model that has always felt a bit, shall we say, imaginative. But now, the lights have flickered on, the music has stopped, and a rather stern-looking group of politicians is standing by the door with the bill. I’m talking, of course, about the growing political pressure to rein in drug prices, a reckoning that feels long overdue.
When a figure like a US President gives 17 of the world’s largest drug companies a 60-day ultimatum to slash their prices, you have to sit up and take notice. This isn’t just political theatre. It’s a direct assault on the fortress of pharmaceutical pricing. The demand is brutally simple: why should an American pay several times more for a pill than a German or a Canadian? It’s a question that, until now, has been met with a flurry of complex justifications about research costs. To me, it looks like the jig may finally be up.
This new reality, should it stick, could create a fascinating shift in the market. When the purveyors of eye-wateringly expensive branded drugs are forced to offer a discount, where does the smart money look? I think it looks towards the companies that were never invited to the fancy party in the first place. The ones who have been quietly building their businesses on a simple premise: making healthcare more affordable.
Think of the generic drug manufacturers. They are the budget airlines of the pharma world. They don’t offer fancy lounges or complimentary cocktails, but they get you to the same destination for a fraction of the price. Companies like Perrigo and Teva Pharmaceutical Industries have built their entire empires on this model. As pressure mounts on their branded rivals, their position could strengthen considerably. They stand to gain market share not through clever marketing, but through sheer economic sense. It’s a compelling narrative for any investor with a pragmatic streak.
Then you have the enablers, the companies that help consumers navigate this confusing landscape. A platform like GoodRx, which helps people find the cheapest place to buy their prescriptions, becomes indispensable in this environment. It thrives on price consciousness. The more people question the cost of their medicine, the more valuable a service that provides clarity and savings becomes. It’s a business model that seems perfectly aligned with the direction of travel.
Putting these pieces together forms a clear investment theme. It’s not about betting on a single company, but on a broader market shift towards affordability and transparency. It’s a strategy that acknowledges the changing dynamics of the entire healthcare ecosystem. For those interested in this specific angle, exploring a curated basket of relevant companies, such as the Navigating Pharma Price Controls theme, could be a logical way to approach it.
Of course, let’s not get carried away. Investing based on political whims is a risky game. Policies can be watered down, delayed by legal challenges, or reversed by the next administration. Big Pharma employs armies of lobbyists for a reason, and their ability to protect their interests should never be underestimated. The generic drug market itself is fiercely competitive. This is not a guaranteed win, but rather a calculated look at a powerful and potentially long-term trend. The path will likely be volatile, but the underlying logic, to me, feels sound.
View the full Basket:Navigating Pharma Price Controls
View the full Basket:Navigating Pharma Price Controls
This article is marketing material and should not be construed as investment advice. No information set out in this article be considered, as advice, recommendation, offer, or a solicitation, to buy or sell any financial product, nor is it financial, investment, or trading advice. Any references to specific financial product or investment strategy are for illustrative / educational purposes only and subject to change without notice. It is the investor’s responsibility to evaluate any prospective investment, assess their own financial situation, and seek independent professional advice. Past performance is not indicative of future results. Please refer to our Risk Disclosure.
Published on 12 September 2026
Read article
Published on 12 September 2026
Read article
Published on 12 September 2026
Read article
Published on 11 September 2026
Read article
Published on 11 September 2026
Read article